Catalyst event

SAMSUNG C&T Corp (028260)

From Akros SCHK HK-Korea High Beta Factor Index (ASHKHBT)

Samsung Biologics reported preliminary second-quarter 2026 revenue of KRW 1.321 trillion and operating profit of KRW 586.4 billion.

Korean translation

삼성바이오로직스는 2026년 2분기 잠정 매출 1조3,209억원 및 영업이익 5,864억원을 발표함.